EXELIXIS, INC. (EXEL) Latest Filing Signal
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for EXELIXIS, INC.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, EXELIXIS, INC.'s filing signal
turned positive.
earningsVibe SuperAnalyst™ Verdict:
TURNED POSITIVE
Signal Performance — Stock Price Since Filing
30-Day Change
-4.21%
from filing date
60-Day Change
+3.00%
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Continuing Positive
GEMINI
Continuing Positive
CLAUDE
Turned Positive
CHATGPT
Continuing Positive
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does EXELIXIS, INC. actually do?
Answer:
Exelixis is an oncology-focused biopharmaceutical company that develops and commercializes innovative medicines for cancer treatment. Its primary revenue driver is CABOMETYX (cabozantinib), a tyrosine kinase inhibitor approved for advanced renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors, with sales accounting for the majority of its revenue. The company also markets COMETRIQ for medullary thyroid cancer and is advancing its pipeline with lead asset zanzalintinib, currently under FDA review for colorectal cancer. Exelixis operates globally, with key collaborations for the commercialization of CABOMETYX in territories outside the U.S. and Japan, and invests heavily in research and development to expand its portfolio of small molecule and biotherapeutic candidates.
Question:
What are EXELIXIS, INC.'s revenue drivers?
Answer:
Net product revenues from CABOMETYX and COMETRIQ, and royalties earned from collaboration agreements with international partners for cabozantinib sales.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required